Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
Recruiting at2 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Clearside Biomedical, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
Research Team
TC
Thomas Ciulla, MD
Principal Investigator
Clearside Biomedical, Inc.
Eligibility Criteria
Inclusion Criteria
diagnosis of non-infectious intermediate, posterior or pan-uveitis
Treatment Details
Interventions
- Triamcinolone Acetonide (Triesence®) (Corticosteroid)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: triamcinolone acetonide (Triesence®)Experimental Treatment1 Intervention
TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Clearside Biomedical, Inc.
Lead Sponsor
Trials
14
Recruited
1,300+